{"ticker": {"uuid": "55a90a56-7002-42a2-a06d-1a79ab21f0ea", "symbol": "CVKD", "name": "Cadrenal Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPRWtLNFdqbW9QS0gxUFVSN1J2clFKLWZZNTl4MjFUNHhhWVdrZm5VZDkxelFja2xlUnRFYUFpRkQtYnVZd29pZlJnRFlrTXhmZWNPRzUwWmdoWTlPaHJLV244U3lOQ0MxR1RfVk50RUVZaXdDS014WERUSlZlbUVWZ3JGRWJWczk5aDlHd1M0RWpodzJhdzUzSWp2QVVoWktlZEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:00:31+00:00", "published_display": "15 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares", "summary": "Cadrenal Therapeutics has filed to register for resale up to 2.94 million shares of common stock, which includes shares associated with pre-funded, Series C-1, and Series C-2 warrants from a recent PIPE financing, as well as placement agent warrants. The company will not receive ", "url": "https://www.stocktitan.net/sec-filings/CVKD/s-3-cadrenal-therapeutics-inc-shelf-registration-statement-8a499cb735bd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:10:27", "published_display": "13 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cadrenal Therapeutics\u2019 Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress", "summary": "Cadrenal Therapeutics announced late-breaking Phase 2 clinical data for its 12-LOX inhibitor CAD-1005, showing a greater than 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). The data, presented at the ISTH 2026 Congress, highlighted CAD", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326228/0/en/Cadrenal-Therapeutics-Late-Breaking-Phase-2-Data-Demonstrate-Greater-Than-25-Reduction-in-Thrombotic-Events-in-HIT-for-First-in-Class-12-LOX-Inhibitor-CAD-1005-at-ISTH-2026-Congres.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:41:49", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal presents phase 2 data for CAD-1005 at ISTH congress", "summary": "Cadrenal Therapeutics presented Phase 2 clinical trial data for CAD-1005, a 12-lipoxygenase inhibitor, at the ISTH Congress, showing a reduction in thrombotic events for HIT patients. Despite positive clinical outcomes and the drug being Phase 3-ready with FDA Orphan Drug and Fas", "url": "https://www.investing.com/news/company-news/cadrenal-presents-phase-2-data-for-cad1005-at-isth-congress-93CH-4788655", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:49", "published_display": "13 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026", "summary": "Cadrenal Therapeutics announced that its Chief Medical Officer, Dr. James J. Ferguson III, will resign effective July 31, 2026. The company is actively searching for a replacement and is negotiating separation terms with Dr. Ferguson. This transition introduces potential leadersh", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-2cc82ccf7bfb.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:40:37", "published_display": "10 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026", "summary": "Cadrenal Therapeutics, Inc. announced the resignation of James J. Ferguson III from his position as Chief Medical Officer, effective July 31, 2026. Dr. Ferguson advised the Board of Directors of his decision on July 7, 2026. The company is actively searching for a replacement and", "url": "https://www.marketscreener.com/news/cadrenal-therapeutics-inc-announces-resignation-of-james-j-ferguson-iii-from-chief-medical-office-ce7f5edfdd8af32c", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T14:09:35", "published_display": "10 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE85b3lIY3NYLTJ1Q0RjMTd2NV96Y1BxdWNKY3Y1M2wyQmxHSGZtckppNGE1cHBnT0tXaFdwSExWQy1yMjd1ZGw2bU9PeVhPTUp2NXJYeA?oc=5", "source_name": "Benzinga", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics CEO sells $22,422 in stock", "summary": "Cadrenal Therapeutics CEO Pham Quang X sold 7,400 shares of company stock worth $22,422 on June 29, 2026, under a pre-arranged trading plan. Despite the insider sale and a significant year-over-year stock price drop, InvestingPro analysis suggests the stock is undervalued. The co", "url": "https://www.investing.com/news/insider-trading-news/cadrenal-therapeutics-ceo-sells-22422-in-stock-93CH-4772259", "source_name": "Investing.com", "published_at": "2026-07-03T00:11:32", "published_display": "03 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Secures Private Placement to Extend Runway", "summary": "Cadrenal Therapeutics has secured a private placement of shares and warrants, raising approximately $3 million upfront with the potential for an additional $5.8 million if warrants are fully exercised. This financing is expected to extend the company's cash runway into early 2027", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3107553/cadrenal-therapeutics-secures-private-placement-to-extend-runway/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T21:39:14", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes", "summary": "Cadrenal Therapeutics (CVKD) Chairman and CEO Quang Pham sold 7,400 shares of common stock at a weighted average price of $3.03 per share on June 29, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Pham directly holds 98,589 shares and indirectly o", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-f31bf4b49fd5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T03:09:29", "published_display": "02 Jul 2026 03:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants", "summary": "Cadrenal Therapeutics has raised $3.0 million through a private placement involving pre-funded and common warrants with an institutional investor. The funds will be used for working capital. The company also entered into a Registration Rights Agreement to facilitate the resale of", "url": "https://www.tradingview.com/news/tradingview:5f2f6c5cee40f:0-cadrenal-therapeutics-raises-3-0-million-in-private-placement-of-pre-funded-and-common-warrants/", "source_name": "TradingView", "published_at": "2026-07-01T21:40:58", "published_display": "01 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement", "summary": "Cadrenal Therapeutics announced a private placement deal with an institutional investor, expected to generate $3 million in gross proceeds upfront and potentially an additional $5.8 million from warrant exercises, totaling up to $8.8 million. The funds are earmarked for working c", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-29bcd8476ee0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:58", "published_display": "01 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$CVKD stock is down 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPMWtoUmpra0FpT0pnS3VPVGk2ZjU1LUZvMkh2UFctTnlobzJ2Z1pmb2I4eHZuNDhHSUp0aVVzam1NNGdpenNncW1oSmxIalZhMG5WbkhXY3pxLWtpejNqQk53UFk1V21Ea0RQMlpUbGI4UklUYVNPZDE3Q0xUQUtweWZ2RTJGc1FvckRsZ2tLLWk1WXQ1WnRqREM0aW5ZMTFudjFj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T19:41:00+00:00", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "Cadrenal Therapeutics Inc. announced a private placement priced at-the-market under Nasdaq rules, potentially raising up to $8.8 million. The offering includes $3 million upfront from the sale of common stock and warrants, with an additional $5.8 million possible if the warrants ", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-8-8-000000641.html", "source_name": "Market source", "published_at": "2026-07-01T12:10:48", "published_display": "01 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal raises $3M now, with $5.8M more possible from warrants", "summary": "Cadrenal Therapeutics announced a private placement to raise $3 million upfront from the sale of common shares and warrants, with the potential for an additional $5.8 million if all warrants are fully exercised. The company expects the initial proceeds to extend its cash runway i", "url": "https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-up-to-8-8-million-private-placement-gdul1suehobb.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:10:48", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500, Dow Futures Slip After Historic First-Half Rally As Investors Await Labor Data, Fed Signals: Why NKE, TSLA, NIO, MU, LUNR, CVKD Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxPOEgxXzRsczlnS3lEb09EbU0xMXFld3p3NUs1b0ZJTjlzT0hwci1meUNzQ2xNMTFIalhpd2M4MzFhQTJTQkluV1dnSENhTWVKSXh2VWt4RHR6Zm51RlBiZVVQeUZOd0xEY1UzSmotc0VUcUo4UDJyRzgzY3NNaC0wUTgzYU5mcXRxZmV4ajNTYno1ZkFRX1RhV2V6OEV3SXhldFAzV09mVm5SZ1NNUGpyaHA5ZGg5d2pVNG9sTnVhU0ZGbXQwX25Tb2pTVUtBcTVGaVZsU1FSSldmSWd0emZsQlkxOXUya1lZM1Z2VGZQYjhMcGRBS25KdjlZU3hFRGtaME9GdU9YbjA1WDNYQlgyRUU1R09RWXpQNzR4aDJsN2trWG05dFhYdzB3RDhLaE11YkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-01T09:25:31+00:00", "published_display": "01 Jul 2026 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cadrenal-therapeutics-prices-private-placement-075512366.html", "source_name": "MT Newswires", "published_at": "2026-07-01T07:55:12+00:00", "published_display": "01 Jul 2026 07:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQNDRuREN0aTRqMjBBTEpCaS1tZlR3WHVVYksyYURfY19LRUpMRkZLcE94TlRtU3RjWlEwVTY1WTdPVVUxclJ5UHp2dnY3TXJWb1FxZ1hkYjUteTlseFR1Y1RkcFhBQk43TGVkTGlmYUl1WV9vWGw4YWs0UXNSdGx0V2xRVzJ1d3RTaUx4bmFIMEx3NnJ6S3V1SHlMS2t4WEh2d3ppUEYxUUNpaTYxbTlGemtXTjNEN3FUZXVGRHlXUGhkRUFwdjd5Y1JJQzBjWnhQSWZQOWpkcmg4c3BoWkJR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down", "summary": "Cadrenal Therapeutics announced a private placement offering of shares and warrants expected to raise $3 million initially, with potential additional proceeds of $5.8 million, to extend its cash runway. This news caused the company's stock (CVKD) to plunge over 11% in pre-market ", "url": "https://www.rttnews.com/3663961/cadrenal-therapeutics-enters-upto-8-8-mln-private-placement-to-extend-cash-runway-stock-down.aspx", "source_name": "RTTNews", "published_at": "2026-07-01T06:38:00", "published_display": "01 Jul 2026 06:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics raises $3 million in private placement", "summary": "Cadrenal Therapeutics, Inc. has raised $3 million through a private placement with a healthcare-focused institutional investor. The biopharmaceutical company will issue 960,000 shares or pre-funded warrants, with potential additional proceeds of $5.8 million if all accompanying w", "url": "https://www.investing.com/news/company-news/cadrenal-therapeutics-raises-3-million-in-private-placement-93CH-4769272", "source_name": "Investing.com", "published_at": "2026-07-01T00:39:55", "published_display": "01 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Names Sharp Interim CFO", "summary": "Cadrenal Therapeutics has appointed Brian Sharp as its interim Chief Financial Officer, effective immediately. Sharp, previously a partner at the accounting firm BDO and having experience with public biotech companies, steps into the role after the resignation of the previous CFO", "url": "https://www.moomoo.com/news/post/72213266/cadrenal-therapeutics-names-sharp-interim-cfo?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T22:39:09", "published_display": "29 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes", "summary": "Cadrenal Therapeutics appointed John P. Sharp as interim Chief Financial Officer, replacing Quang X. Pham, who remains Chairman and CEO. Sharp will provide services via Lohman & Associates at $455/hour for up to 24 hours weekly. Additionally, director Steven Zelenkofske resigned,", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-497496925334.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:20:10", "published_display": "29 Jun 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on a Form 4 filing for Cadrenal Therapeutics Inc (CVKD) dated June 26. It indicates that the company's stock symbol is CVKD and provides its price performance at the time of publication. The document itself seems to be a brief announcement of the regulatory f", "url": "https://ng.investing.com/news/stock-market-news/form-4-cadrenal-therapeutics-inc-for-26-june-93CH-2576797", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T21:39:52", "published_display": "27 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com", "summary": "Cadrenal Therapeutics CEO Quang X. Pham sold 11,156 shares of the company's common stock for a total of $33,919, executed under a Rule 10b5-1 trading arrangement. These sales occurred on June 25th and 26th, 2026, as the stock experienced a 13% decline over the past week. Despite ", "url": "https://m.za.investing.com/news/stock-market-news/cadrenal-therapeutics-ceo-pham-sells-33919-in-stock-93CH-4346631?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T08:10:44", "published_display": "27 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cadrenal Therapeutics, Inc. \u2013 NASDAQ:CVKD", "summary": "This article provides financial information for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), specifically focusing on its \"Price to earnings forward\" metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials, news, a", "url": "https://www.tradingview.com/symbols/NASDAQ-CVKD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:53", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan", "summary": "Cadrenal Therapeutics' CEO and Chairman, Quang X. Pham, reported selling 11,156 shares of common stock in late June 2026 under a pre-arranged Rule 10b5-1 trading arrangement adopted in September 2025. The sales were executed in two transactions at prices of $3.00 and a weighted a", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-84da0552a7c0.html", "source_name": "Stock Titan", "published_at": "2026-06-27T01:39:53", "published_display": "27 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock.", "summary": "Cadrenal Therapeutics' Chairman, CEO, and Interim CFO Pham Quang X sold shares worth $39,829 under a Rule 10b5-1 trading plan. The sales occurred on June 22nd and 23rd, 2026, at weighted average prices of $3.55 and $3.20 respectively, following a 73% decline in the company's stoc", "url": "https://www.investing.com/news/insider-trading-news/cadrenal-therapeutics-chairman-and-ceo-pham-sells-39829-in-stock-93CH-4759179", "source_name": "Investing.com", "published_at": "2026-06-24T23:41:29", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades", "summary": "Cadrenal Therapeutics CEO and Chairman Quang Pham sold 11,444 shares of common stock in June 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales, totaling approximately $39,829, were open-market transactions at weighted average prices of $3.55 ", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-66dcb1e3e141.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:41:29", "published_display": "24 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Cadrenal Therapeutics Inc. on June 24th. The filing indicates insider trading activity for the company. The stock symbol associated with Cadrenal Therapeutics Inc. is CVKD.", "url": "https://ca.investing.com/news/stock-market-news/form-4-cadrenal-therapeutics-inc-for-24-june-93CH-4706300", "source_name": "Investing.com Canada", "published_at": "2026-06-24T21:41:29", "published_display": "24 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug data selected for presentation at Paris congress", "summary": "Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis. This presentation will cover results from a Phase 2 t", "url": "https://www.investing.com/news/company-news/cadrenals-hit-drug-data-selected-for-presentation-at-paris-congress-93CH-4758023", "source_name": "Investing.com", "published_at": "2026-06-24T13:41:29", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T12:00:00+00:00", "published_display": "24 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug data selected for presentation at Paris congress By Investing.com", "summary": "Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been selected for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis in Paris. The presentation will detail results from a ", "url": "https://m.au.investing.com/news/stock-market-news/cadrenals-hit-drug-data-selected-for-presentation-at-paris-congress-93CH-4502440?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-24T12:40:05", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug gets late-breaking oral slot at ISTH 2026", "summary": "Cadrenal Therapeutics announced that its CAD-1005 Phase 2 data for heparin-induced thrombocytopenia (HIT) has been selected for a late-breaking oral presentation at the ISTH 2026 Congress in Paris. The company highlights CAD-1005 as a first-in-class 12-lipoxygenase inhibitor and ", "url": "https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-selection-of-cad-1005-phase-2-study-5stbe42ry5n3.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:40:05", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces Selection of CAD-1005 Phase", "summary": "Cadrenal Therapeutics (Nasdaq: CVKD) announced that its Phase 2 study for CAD-1005, a 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT), has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This is the first randomized, blinded, pl", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316790/0/en/Cadrenal-Therapeutics-Announces-Selection-of-CAD-1005-Phase-2-Study-for-Late-Breaking-Oral-Presentation-at-ISTH-2026-Congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T11:40:05", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-seek-us-fda-135344221.html", "source_name": "MT Newswires", "published_at": "2026-06-18T13:53:44+00:00", "published_display": "18 Jun 2026 13:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T13:00:00+00:00", "published_display": "18 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTzdEenJDdVdUeDZOaGR1cVFXRTRKeDBtV1kyMkx2VzF4T1FqQXY3eWdPeF90SENOMGIxaGVaOXhtSF9ZcDNFY1NtcklrR2FFSWQwQWlVUVgxeGZKdVMyaUNtZFg0MHJqTFNnLXRQWXNpS2ZORnlMZE84MTlQTndIOVJsTVo3SWdocV96NXB6NDl3R2ZNMUczOXRGclZZM0tyejN4VC1KRGE1RV9vdTlBWTlGVG9LQlFTRGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pediatric voucher play: Cadrenal (NASDAQ: CVKD) eyes tecarfarin RPDD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPalhGTU5DR2dyZHZ4MzJUUlliT2hKUWo3UjJuQXpYMFJHSHRnZFpBdWlOZ2pzUlhBSjBLSmdNRkpiemFuNlhuN1laVjJBcFBrenl2ckx0eElGNFFWR0llazRsLUhBblg3cDctX2tLVVJfcGhKNGlZOUJTX2pBa1ZsUl82UzJMV2RlRW5pQlBqY1pyYW1PX3dJV2N6TGhtNXNjMkwxX183X19lX3k2a2RvdHkwOVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-advances-multi-indication-123000241.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:30:00+00:00", "published_display": "15 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at\u00a0BIO International Convention 2026 Partnering Event", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-showcase-phase-3-130000080.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T13:00:00+00:00", "published_display": "03 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-participate-lytham-partners-203000786.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZVV3ZDZrMHlvSkozTEZaNDM3eHg4RVNvTjFvN0s1bVFGQktvUWV0Vmc0LXZJVmFMYTRMOEU4TkhVSUhPcTB5cVkwbFZ1ckFYOUZmYW5fUTlCNFZGQVE3TjN4TDRHSWpOdm16ZlpyODdCZFprVGRONEpfSUYwSUh1SVV6UWVGV2p5MmlfSDg4bnRRc01ub2d5cHZjeUc3Uk90cVVWS1R3SW9FQnlPVU8yR244WWhIb2dPT3dSdFUzMnhYYlk?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGY4dmJrWXBHUEVvcmFKV1h2eFljbkFMeEV4YW5wN0Y4Z241c2tuMDA3MDFvYVRiektPMC1HRjhiSERPbjN3X2tibzhTQXZDbUNRMEJHLUNEZm14OVl1ZVd3S2lMVnBCclNoR0lJR25ydWE2ekNZQ1VtZlpNVFk5YmxYQnBXQXBHX19US19CN3RtaklUXzFxY0pfSkpYek91R1Z0R3hxbkctLWtPazhV?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPRWtLNFdqbW9QS0gxUFVSN1J2clFKLWZZNTl4MjFUNHhhWVdrZm5VZDkxelFja2xlUnRFYUFpRkQtYnVZd29pZlJnRFlrTXhmZWNPRzUwWmdoWTlPaHJLV244U3lOQ0MxR1RfVk50RUVZaXdDS014WERUSlZlbUVWZ3JGRWJWczk5aDlHd1M0RWpodzJhdzUzSWp2QVVoWktlZEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T21:00:31+00:00", "published_display": "15 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) files resale for 2.94M warrant shares", "summary": "Cadrenal Therapeutics has filed to register for resale up to 2.94 million shares of common stock, which includes shares associated with pre-funded, Series C-1, and Series C-2 warrants from a recent PIPE financing, as well as placement agent warrants. The company will not receive ", "url": "https://www.stocktitan.net/sec-filings/CVKD/s-3-cadrenal-therapeutics-inc-shelf-registration-statement-8a499cb735bd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T21:10:27", "published_display": "13 Jul 2026 21:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics\u2019 Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress", "summary": "Cadrenal Therapeutics announced late-breaking Phase 2 clinical data for its 12-LOX inhibitor CAD-1005, showing a greater than 25% reduction in thrombotic events in patients with Heparin-Induced Thrombocytopenia (HIT). The data, presented at the ISTH 2026 Congress, highlighted CAD", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326228/0/en/Cadrenal-Therapeutics-Late-Breaking-Phase-2-Data-Demonstrate-Greater-Than-25-Reduction-in-Thrombotic-Events-in-HIT-for-First-in-Class-12-LOX-Inhibitor-CAD-1005-at-ISTH-2026-Congres.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T12:41:49", "published_display": "13 Jul 2026 12:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal presents phase 2 data for CAD-1005 at ISTH congress", "summary": "Cadrenal Therapeutics presented Phase 2 clinical trial data for CAD-1005, a 12-lipoxygenase inhibitor, at the ISTH Congress, showing a reduction in thrombotic events for HIT patients. Despite positive clinical outcomes and the drug being Phase 3-ready with FDA Orphan Drug and Fas", "url": "https://www.investing.com/news/company-news/cadrenal-presents-phase-2-data-for-cad1005-at-isth-congress-93CH-4788655", "source_name": "Investing.com", "published_at": "2026-07-13T12:41:49", "published_display": "13 Jul 2026 12:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) Chief Medical Officer James Ferguson to step down July 31, 2026", "summary": "Cadrenal Therapeutics announced that its Chief Medical Officer, Dr. James J. Ferguson III, will resign effective July 31, 2026. The company is actively searching for a replacement and is negotiating separation terms with Dr. Ferguson. This transition introduces potential leadersh", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-2cc82ccf7bfb.html", "source_name": "Stock Titan", "published_at": "2026-07-10T19:40:37", "published_display": "10 Jul 2026 19:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026", "summary": "Cadrenal Therapeutics, Inc. announced the resignation of James J. Ferguson III from his position as Chief Medical Officer, effective July 31, 2026. Dr. Ferguson advised the Board of Directors of his decision on July 7, 2026. The company is actively searching for a replacement and", "url": "https://www.marketscreener.com/news/cadrenal-therapeutics-inc-announces-resignation-of-james-j-ferguson-iii-from-chief-medical-office-ce7f5edfdd8af32c", "source_name": "www.marketscreener.com", "published_at": "2026-07-10T14:09:35", "published_display": "10 Jul 2026 14:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) Stock Analysis Report | Financials & Insights", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVEFVX3lxTE85b3lIY3NYLTJ1Q0RjMTd2NV96Y1BxdWNKY3Y1M2wyQmxHSGZtckppNGE1cHBnT0tXaFdwSExWQy1yMjd1ZGw2bU9PeVhPTUp2NXJYeA?oc=5", "source_name": "Benzinga", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics CEO sells $22,422 in stock", "summary": "Cadrenal Therapeutics CEO Pham Quang X sold 7,400 shares of company stock worth $22,422 on June 29, 2026, under a pre-arranged trading plan. Despite the insider sale and a significant year-over-year stock price drop, InvestingPro analysis suggests the stock is undervalued. The co", "url": "https://www.investing.com/news/insider-trading-news/cadrenal-therapeutics-ceo-sells-22422-in-stock-93CH-4772259", "source_name": "Investing.com", "published_at": "2026-07-03T00:11:32", "published_display": "03 Jul 2026 00:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Secures Private Placement to Extend Runway", "summary": "Cadrenal Therapeutics has secured a private placement of shares and warrants, raising approximately $3 million upfront with the potential for an additional $5.8 million if warrants are fully exercised. This financing is expected to extend the company's cash runway into early 2027", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3107553/cadrenal-therapeutics-secures-private-placement-to-extend-runway/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T21:39:14", "published_display": "02 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO sells 7,400 shares, retains direct and trust stakes", "summary": "Cadrenal Therapeutics (CVKD) Chairman and CEO Quang Pham sold 7,400 shares of common stock at a weighted average price of $3.03 per share on June 29, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Pham directly holds 98,589 shares and indirectly o", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-f31bf4b49fd5.html", "source_name": "Stock Titan", "published_at": "2026-07-02T03:09:29", "published_display": "02 Jul 2026 03:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Raises $3.0 Million in Private Placement of Pre-Funded and Common Warrants", "summary": "Cadrenal Therapeutics has raised $3.0 million through a private placement involving pre-funded and common warrants with an institutional investor. The funds will be used for working capital. The company also entered into a Registration Rights Agreement to facilitate the resale of", "url": "https://www.tradingview.com/news/tradingview:5f2f6c5cee40f:0-cadrenal-therapeutics-raises-3-0-million-in-private-placement-of-pre-funded-and-common-warrants/", "source_name": "TradingView", "published_at": "2026-07-01T21:40:58", "published_display": "01 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) lines up up to $8.8M via private placement", "summary": "Cadrenal Therapeutics announced a private placement deal with an institutional investor, expected to generate $3 million in gross proceeds upfront and potentially an additional $5.8 million from warrant exercises, totaling up to $8.8 million. The funds are earmarked for working c", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-29bcd8476ee0.html", "source_name": "Stock Titan", "published_at": "2026-07-01T21:40:58", "published_display": "01 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$CVKD stock is down 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPMWtoUmpra0FpT0pnS3VPVGk2ZjU1LUZvMkh2UFctTnlobzJ2Z1pmb2I4eHZuNDhHSUp0aVVzam1NNGdpenNncW1oSmxIalZhMG5WbkhXY3pxLWtpejNqQk53UFk1V21Ea0RQMlpUbGI4UklUYVNPZDE3Q0xUQUtweWZ2RTJGc1FvckRsZ2tLLWk1WXQ1WnRqREM0aW5ZMTFudjFj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T19:41:00+00:00", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules", "summary": "Cadrenal Therapeutics Inc. announced a private placement priced at-the-market under Nasdaq rules, potentially raising up to $8.8 million. The offering includes $3 million upfront from the sale of common stock and warrants, with an additional $5.8 million possible if the warrants ", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-8-8-000000641.html", "source_name": "Market source", "published_at": "2026-07-01T12:10:48", "published_display": "01 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal raises $3M now, with $5.8M more possible from warrants", "summary": "Cadrenal Therapeutics announced a private placement to raise $3 million upfront from the sale of common shares and warrants, with the potential for an additional $5.8 million if all warrants are fully exercised. The company expects the initial proceeds to extend its cash runway i", "url": "https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-up-to-8-8-million-private-placement-gdul1suehobb.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:10:48", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500, Dow Futures Slip After Historic First-Half Rally As Investors Await Labor Data, Fed Signals: Why NKE, TSLA, NIO, MU, LUNR, CVKD Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgJBVV95cUxPOEgxXzRsczlnS3lEb09EbU0xMXFld3p3NUs1b0ZJTjlzT0hwci1meUNzQ2xNMTFIalhpd2M4MzFhQTJTQkluV1dnSENhTWVKSXh2VWt4RHR6Zm51RlBiZVVQeUZOd0xEY1UzSmotc0VUcUo4UDJyRzgzY3NNaC0wUTgzYU5mcXRxZmV4ajNTYno1ZkFRX1RhV2V6OEV3SXhldFAzV09mVm5SZ1NNUGpyaHA5ZGg5d2pVNG9sTnVhU0ZGbXQwX25Tb2pTVUtBcTVGaVZsU1FSSldmSWd0emZsQlkxOXUya1lZM1Z2VGZQYjhMcGRBS25KdjlZU3hFRGtaME9GdU9YbjA1WDNYQlgyRUU1R09RWXpQNzR4aDJsN2trWG05dFhYdzB3RDhLaE11YkE?oc=5", "source_name": "TradingView", "published_at": "2026-07-01T09:25:31+00:00", "published_display": "01 Jul 2026 09:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cadrenal-therapeutics-prices-private-placement-075512366.html", "source_name": "MT Newswires", "published_at": "2026-07-01T07:55:12+00:00", "published_display": "01 Jul 2026 07:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces $3 Million Private Placement with Potential Additional $5.8 Million from Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxQNDRuREN0aTRqMjBBTEpCaS1tZlR3WHVVYksyYURfY19LRUpMRkZLcE94TlRtU3RjWlEwVTY1WTdPVVUxclJ5UHp2dnY3TXJWb1FxZ1hkYjUteTlseFR1Y1RkcFhBQk43TGVkTGlmYUl1WV9vWGw4YWs0UXNSdGx0V2xRVzJ1d3RTaUx4bmFIMEx3NnJ6S3V1SHlMS2t4WEh2d3ppUEYxUUNpaTYxbTlGemtXTjNEN3FUZXVGRHlXUGhkRUFwdjd5Y1JJQzBjWnhQSWZQOWpkcmg4c3BoWkJR?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Enters Upto $8.8 Mln Private Placement To Extend Cash Runway; Stock Down", "summary": "Cadrenal Therapeutics announced a private placement offering of shares and warrants expected to raise $3 million initially, with potential additional proceeds of $5.8 million, to extend its cash runway. This news caused the company's stock (CVKD) to plunge over 11% in pre-market ", "url": "https://www.rttnews.com/3663961/cadrenal-therapeutics-enters-upto-8-8-mln-private-placement-to-extend-cash-runway-stock-down.aspx", "source_name": "RTTNews", "published_at": "2026-07-01T06:38:00", "published_display": "01 Jul 2026 06:38", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics raises $3 million in private placement", "summary": "Cadrenal Therapeutics, Inc. has raised $3 million through a private placement with a healthcare-focused institutional investor. The biopharmaceutical company will issue 960,000 shares or pre-funded warrants, with potential additional proceeds of $5.8 million if all accompanying w", "url": "https://www.investing.com/news/company-news/cadrenal-therapeutics-raises-3-million-in-private-placement-93CH-4769272", "source_name": "Investing.com", "published_at": "2026-07-01T00:39:55", "published_display": "01 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Names Sharp Interim CFO", "summary": "Cadrenal Therapeutics has appointed Brian Sharp as its interim Chief Financial Officer, effective immediately. Sharp, previously a partner at the accounting firm BDO and having experience with public biotech companies, steps into the role after the resignation of the previous CFO", "url": "https://www.moomoo.com/news/post/72213266/cadrenal-therapeutics-names-sharp-interim-cfo?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T22:39:09", "published_display": "29 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes", "summary": "Cadrenal Therapeutics appointed John P. Sharp as interim Chief Financial Officer, replacing Quang X. Pham, who remains Chairman and CEO. Sharp will provide services via Lohman & Associates at $455/hour for up to 24 hours weekly. Additionally, director Steven Zelenkofske resigned,", "url": "https://www.stocktitan.net/sec-filings/CVKD/8-k-cadrenal-therapeutics-inc-reports-material-event-497496925334.html", "source_name": "Stock Titan", "published_at": "2026-06-29T21:20:10", "published_display": "29 Jun 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cadrenal Therapeutics Inc For: 26 June By Investing.com", "summary": "This article reports on a Form 4 filing for Cadrenal Therapeutics Inc (CVKD) dated June 26. It indicates that the company's stock symbol is CVKD and provides its price performance at the time of publication. The document itself seems to be a brief announcement of the regulatory f", "url": "https://ng.investing.com/news/stock-market-news/form-4-cadrenal-therapeutics-inc-for-26-june-93CH-2576797", "source_name": "Investing.com Nigeria", "published_at": "2026-06-27T21:39:52", "published_display": "27 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal therapeutics CEO Pham sells $33,919 in stock By Investing.com", "summary": "Cadrenal Therapeutics CEO Quang X. Pham sold 11,156 shares of the company's common stock for a total of $33,919, executed under a Rule 10b5-1 trading arrangement. These sales occurred on June 25th and 26th, 2026, as the stock experienced a 13% decline over the past week. Despite ", "url": "https://m.za.investing.com/news/stock-market-news/cadrenal-therapeutics-ceo-pham-sells-33919-in-stock-93CH-4346631?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T08:10:44", "published_display": "27 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cadrenal Therapeutics, Inc. \u2013 NASDAQ:CVKD", "summary": "This article provides financial information for Cadrenal Therapeutics, Inc. (NASDAQ: CVKD), specifically focusing on its \"Price to earnings forward\" metric. The content appears to be a financial data page from TradingView, offering an overview of the company's financials, news, a", "url": "https://www.tradingview.com/symbols/NASDAQ-CVKD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:53", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan", "summary": "Cadrenal Therapeutics' CEO and Chairman, Quang X. Pham, reported selling 11,156 shares of common stock in late June 2026 under a pre-arranged Rule 10b5-1 trading arrangement adopted in September 2025. The sales were executed in two transactions at prices of $3.00 and a weighted a", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-84da0552a7c0.html", "source_name": "Stock Titan", "published_at": "2026-06-27T01:39:53", "published_display": "27 Jun 2026 01:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics chairman and CEO Pham sells $39,829 in stock.", "summary": "Cadrenal Therapeutics' Chairman, CEO, and Interim CFO Pham Quang X sold shares worth $39,829 under a Rule 10b5-1 trading plan. The sales occurred on June 22nd and 23rd, 2026, at weighted average prices of $3.55 and $3.20 respectively, following a 73% decline in the company's stoc", "url": "https://www.investing.com/news/insider-trading-news/cadrenal-therapeutics-chairman-and-ceo-pham-sells-39829-in-stock-93CH-4759179", "source_name": "Investing.com", "published_at": "2026-06-24T23:41:29", "published_display": "24 Jun 2026 23:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO Quang Pham sells 11,444 shares in planned 10b5-1 trades", "summary": "Cadrenal Therapeutics CEO and Chairman Quang Pham sold 11,444 shares of common stock in June 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in September 2025. The sales, totaling approximately $39,829, were open-market transactions at weighted average prices of $3.55 ", "url": "https://www.stocktitan.net/sec-filings/CVKD/form-4-cadrenal-therapeutics-inc-insider-trading-activity-66dcb1e3e141.html", "source_name": "Stock Titan", "published_at": "2026-06-24T21:41:29", "published_display": "24 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cadrenal Therapeutics Inc For: 24 June By Investing.com", "summary": "This article reports on a Form 4 filing for Cadrenal Therapeutics Inc. on June 24th. The filing indicates insider trading activity for the company. The stock symbol associated with Cadrenal Therapeutics Inc. is CVKD.", "url": "https://ca.investing.com/news/stock-market-news/form-4-cadrenal-therapeutics-inc-for-24-june-93CH-4706300", "source_name": "Investing.com Canada", "published_at": "2026-06-24T21:41:29", "published_display": "24 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug data selected for presentation at Paris congress", "summary": "Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis. This presentation will cover results from a Phase 2 t", "url": "https://www.investing.com/news/company-news/cadrenals-hit-drug-data-selected-for-presentation-at-paris-congress-93CH-4758023", "source_name": "Investing.com", "published_at": "2026-06-24T13:41:29", "published_display": "24 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T12:00:00+00:00", "published_display": "24 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug data selected for presentation at Paris congress By Investing.com", "summary": "Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been selected for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis in Paris. The presentation will detail results from a ", "url": "https://m.au.investing.com/news/stock-market-news/cadrenals-hit-drug-data-selected-for-presentation-at-paris-congress-93CH-4502440?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-06-24T12:40:05", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal\u2019s HIT drug gets late-breaking oral slot at ISTH 2026", "summary": "Cadrenal Therapeutics announced that its CAD-1005 Phase 2 data for heparin-induced thrombocytopenia (HIT) has been selected for a late-breaking oral presentation at the ISTH 2026 Congress in Paris. The company highlights CAD-1005 as a first-in-class 12-lipoxygenase inhibitor and ", "url": "https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-selection-of-cad-1005-phase-2-study-5stbe42ry5n3.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:40:05", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Announces Selection of CAD-1005 Phase", "summary": "Cadrenal Therapeutics (Nasdaq: CVKD) announced that its Phase 2 study for CAD-1005, a 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT), has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This is the first randomized, blinded, pl", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316790/0/en/Cadrenal-Therapeutics-Announces-Selection-of-CAD-1005-Phase-2-Study-for-Late-Breaking-Oral-Presentation-at-ISTH-2026-Congress.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T11:40:05", "published_display": "24 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-seek-us-fda-135344221.html", "source_name": "MT Newswires", "published_at": "2026-06-18T13:53:44+00:00", "published_display": "18 Jun 2026 13:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-file-fda-rare-130000465.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T13:00:00+00:00", "published_display": "18 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTzdEenJDdVdUeDZOaGR1cVFXRTRKeDBtV1kyMkx2VzF4T1FqQXY3eWdPeF90SENOMGIxaGVaOXhtSF9ZcDNFY1NtcklrR2FFSWQwQWlVUVgxeGZKdVMyaUNtZFg0MHJqTFNnLXRQWXNpS2ZORnlMZE84MTlQTndIOVJsTVo3SWdocV96NXB6NDl3R2ZNMUczOXRGclZZM0tyejN4VC1KRGE1RV9vdTlBWTlGVG9LQlFTRGYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pediatric voucher play: Cadrenal (NASDAQ: CVKD) eyes tecarfarin RPDD", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPalhGTU5DR2dyZHZ4MzJUUlliT2hKUWo3UjJuQXpYMFJHSHRnZFpBdWlOZ2pzUlhBSjBLSmdNRkpiemFuNlhuN1laVjJBcFBrenl2ckx0eElGNFFWR0llazRsLUhBblg3cDctX2tLVVJfcGhKNGlZOUJTX2pBa1ZsUl82UzJMV2RlRW5pQlBqY1pyYW1PX3dJV2N6TGhtNXNjMkwxX183X19lX3k2a2RvdHkwOVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-advances-multi-indication-123000241.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T12:30:00+00:00", "published_display": "15 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at\u00a0BIO International Convention 2026 Partnering Event", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-showcase-phase-3-130000080.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T13:00:00+00:00", "published_display": "03 Jun 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cadrenal-therapeutics-participate-lytham-partners-203000786.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CVKD Stock Retail Sentiment Peaks After FDA Clears Phase 3 Path For Blood Clot Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZVV3ZDZrMHlvSkozTEZaNDM3eHg4RVNvTjFvN0s1bVFGQktvUWV0Vmc0LXZJVmFMYTRMOEU4TkhVSUhPcTB5cVkwbFZ1ckFYOUZmYW5fUTlCNFZGQVE3TjN4TDRHSWpOdm16ZlpyODdCZFprVGRONEpfSUYwSUh1SVV6UWVGV2p5MmlfSDg4bnRRc01ub2d5cHZjeUc3Uk90cVVWS1R3SW9FQnlPVU8yR244WWhIb2dPT3dSdFUzMnhYYlk?oc=5", "source_name": "Stocktwits", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGY4dmJrWXBHUEVvcmFKV1h2eFljbkFMeEV4YW5wN0Y4Z241c2tuMDA3MDFvYVRiektPMC1HRjhiSERPbjN3X2tibzhTQXZDbUNRMEJHLUNEZm14OVl1ZVd3S2lMVnBCclNoR0lJR25ydWE2ekNZQ1VtZlpNVFk5YmxYQnBXQXBHX19US19CN3RtaklUXzFxY0pfSkpYek91R1Z0R3hxbkctLWtPazhV?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 63, "sentiment_summary": {"positive": 13, "negative": 12, "neutral": 38, "score": 52, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 22.35, "count": 40}, {"event": "earnings", "label": "Earnings", "weight": 9.09, "count": 17}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 2.89, "latest_week": "2026-07-10", "one_week_move": -19.7, "four_week_move": -21.9, "twelve_week_move": -44.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.510529, "market_dynamics_buy_signal": false, "relative_strength": -71.691985, "fair_value_gap": -73.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.3723, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-19.7% over one week, -21.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 8}, {"label": "GlobeNewswire", "count": 7}, {"label": "Investing.com", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "Quiver Quantitative", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 40}, {"label": "Earnings", "count": 17}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-19.7% over one week, -21.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing"}], "updated_at": "2026-07-16T03:29:33.488371+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}